RU2012154447A - Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций - Google Patents
Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций Download PDFInfo
- Publication number
- RU2012154447A RU2012154447A RU2012154447/04A RU2012154447A RU2012154447A RU 2012154447 A RU2012154447 A RU 2012154447A RU 2012154447/04 A RU2012154447/04 A RU 2012154447/04A RU 2012154447 A RU2012154447 A RU 2012154447A RU 2012154447 A RU2012154447 A RU 2012154447A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- group
- compound
- cycloalkyl
- alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 48
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 title claims abstract 40
- 230000004064 dysfunction Effects 0.000 title claims abstract 25
- 230000000926 neurological effect Effects 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title claims 2
- 101150025480 Grm4 gene Proteins 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 106
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 104
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 82
- 150000001875 compounds Chemical class 0.000 claims abstract 80
- 229910052799 carbon Inorganic materials 0.000 claims abstract 70
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 58
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims abstract 48
- 230000000694 effects Effects 0.000 claims abstract 42
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 39
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 claims abstract 39
- 125000003118 aryl group Chemical group 0.000 claims abstract 36
- 241000124008 Mammalia Species 0.000 claims abstract 32
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 230000005062 synaptic transmission Effects 0.000 claims abstract 9
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 66
- 229910052739 hydrogen Inorganic materials 0.000 claims 46
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 229910052736 halogen Inorganic materials 0.000 claims 44
- 150000002367 halogens Chemical class 0.000 claims 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 29
- 208000035475 disorder Diseases 0.000 claims 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 230000003389 potentiating effect Effects 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 201000000980 schizophrenia Diseases 0.000 claims 8
- 208000028017 Psychotic disease Diseases 0.000 claims 7
- 208000019901 Anxiety disease Diseases 0.000 claims 6
- 208000018737 Parkinson disease Diseases 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 208000020925 Bipolar disease Diseases 0.000 claims 5
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 5
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- 208000031091 Amnestic disease Diseases 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 208000019430 Motor disease Diseases 0.000 claims 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 3
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000002720 Malnutrition Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 230000001071 malnutrition Effects 0.000 claims 2
- 235000000824 malnutrition Nutrition 0.000 claims 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000027465 Psychotic Affective disease Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 208000030212 nutrition disease Diseases 0.000 claims 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000035923 taste sensation Effects 0.000 claims 1
- 239000010802 sludge Substances 0.000 abstract 1
- 0 Cc(nc(NC(c1ncccc1)=O)[s]1)c1S(Cc1cc(*)ccc1*)(=O)=O Chemical compound Cc(nc(NC(c1ncccc1)=O)[s]1)c1S(Cc1cc(*)ccc1*)(=O)=O 0.000 description 2
- VYDJTWWECBUAEO-UHFFFAOYSA-N CC(C)c(nc(NC(c1ncccc1)=O)[s]1)c1S(C(C)c1ccccc1Cl)(=O)=O Chemical compound CC(C)c(nc(NC(c1ncccc1)=O)[s]1)c1S(C(C)c1ccccc1Cl)(=O)=O VYDJTWWECBUAEO-UHFFFAOYSA-N 0.000 description 1
- PGKLIZKBSJEMLX-UHFFFAOYSA-N CC(C)c1ccc(CS(c2c(C)nc(NC(c3ccccn3)=O)[s]2)(=O)=O)cc1 Chemical compound CC(C)c1ccc(CS(c2c(C)nc(NC(c3ccccn3)=O)[s]2)(=O)=O)cc1 PGKLIZKBSJEMLX-UHFFFAOYSA-N 0.000 description 1
- QFRNZEQLGXIDMF-UHFFFAOYSA-N Cc(nc(NC(c1ccccn1)=O)[s]1)c1S(Cc1ccc(C)cc1)(=O)=O Chemical compound Cc(nc(NC(c1ccccn1)=O)[s]1)c1S(Cc1ccc(C)cc1)(=O)=O QFRNZEQLGXIDMF-UHFFFAOYSA-N 0.000 description 1
- OCVRDYREJYODBM-UHFFFAOYSA-N Cc(nc(NC(c1ncccc1)=O)[s]1)c1S(Cc1ccccc1Cl)(=O)=O Chemical compound Cc(nc(NC(c1ncccc1)=O)[s]1)c1S(Cc1ccccc1Cl)(=O)=O OCVRDYREJYODBM-UHFFFAOYSA-N 0.000 description 1
- ZXIIVXBJJRPTOY-UHFFFAOYSA-N O=C(c1ccccn1)Nc([s]1)nnc1S(Cc1ccccc1)(=O)=O Chemical compound O=C(c1ccccn1)Nc([s]1)nnc1S(Cc1ccccc1)(=O)=O ZXIIVXBJJRPTOY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33392610P | 2010-05-12 | 2010-05-12 | |
| US61/333,926 | 2010-05-12 | ||
| PCT/US2011/036308 WO2011143466A1 (en) | 2010-05-12 | 2011-05-12 | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012154447A true RU2012154447A (ru) | 2014-06-20 |
Family
ID=44914713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012154447/04A RU2012154447A (ru) | 2010-05-12 | 2011-05-12 | Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9192603B2 (enExample) |
| EP (1) | EP2568809A4 (enExample) |
| JP (1) | JP2013526544A (enExample) |
| KR (1) | KR20130079429A (enExample) |
| CN (1) | CN102939006A (enExample) |
| AU (1) | AU2011252974A1 (enExample) |
| BR (1) | BR112012028894A2 (enExample) |
| CA (1) | CA2798514A1 (enExample) |
| IL (1) | IL222854A0 (enExample) |
| MX (1) | MX2012013031A (enExample) |
| RU (1) | RU2012154447A (enExample) |
| SG (1) | SG185414A1 (enExample) |
| WO (1) | WO2011143466A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8618300B2 (en) | 2008-09-04 | 2013-12-31 | Boehringer Ingelheim International Gmbh | Indolizine inhibitors of leukotriene production |
| CA2751176A1 (en) | 2009-01-28 | 2010-08-05 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| JP5690839B2 (ja) | 2009-12-04 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のベンゾイミダゾール阻害薬 |
| PH12013500301A1 (en) | 2010-08-16 | 2013-03-25 | Boehringer Ingelheim Int | Oxadiazole inhibitors of leukotriene production |
| EP2609092B1 (en) | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| US8580825B2 (en) | 2010-09-23 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| AU2011305667A1 (en) | 2010-09-23 | 2013-03-21 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| US8829200B2 (en) | 2010-10-29 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
| EP2635566B1 (en) | 2010-11-01 | 2018-05-16 | Boehringer Ingelheim International GmbH | Benzimidazole inhibitors of leukotriene production |
| WO2012082817A1 (en) | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| MX2014015265A (es) | 2012-06-14 | 2015-08-12 | Basf Se | Metodos plaguicidas que utilizan compuestos de 3-piridiltiazol sustituido y derivados para combatir plagas de animales. |
| SG11201602029VA (en) * | 2013-09-25 | 2016-04-28 | Hoffmann La Roche | Ethynyl derivatives |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016179351A1 (en) | 2015-05-05 | 2016-11-10 | Northwestern University | Treatment of levodopa-induced dyskinesias |
| WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| JP7101177B2 (ja) | 2017-01-10 | 2022-07-14 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としてのヘテロサイクレン誘導体 |
| MX2019008230A (es) | 2017-01-10 | 2019-10-24 | Bayer Ag | Derivados heterociclicos como agentes de control de plagas. |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EA202090467A1 (ru) | 2017-08-16 | 2020-06-18 | Вандербилт Юниверсити | ИНДАЗОЛОВЫЕ СОЕДИНЕНИЯ КАК АЛЛОСТЕРИЧЕСКИЕ ПОТЕНЦИАТОРЫ mGLuR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| SI3752501T1 (sl) | 2018-02-13 | 2023-08-31 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| WO2019169193A1 (en) | 2018-03-01 | 2019-09-06 | Annapurna Bio Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| CA3134635A1 (en) | 2019-04-03 | 2020-10-08 | Aligos Therapeutics, Inc. | Pyrrole compounds |
| AU2020407664A1 (en) | 2019-12-20 | 2022-08-18 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| US20230247994A1 (en) | 2020-07-02 | 2023-08-10 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| EP4333841A1 (en) | 2021-05-04 | 2024-03-13 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE21393T1 (de) | 1982-01-22 | 1986-08-15 | Basf Ag | Thiadiazolderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses. |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6162791A (en) | 1998-03-02 | 2000-12-19 | Apotex Inc. | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| US6468977B1 (en) | 1998-03-02 | 2002-10-22 | Apotex Inc. | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| JP2002506858A (ja) | 1998-03-19 | 2002-03-05 | ファルマシア・アンド・アップジョン・カンパニー | Ｃｍｖ感染症の治療に有用な１，３，４−チアジアゾール |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| WO2005007096A2 (en) | 2003-07-11 | 2005-01-27 | Merck & Co., Inc. | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| EP1983980A4 (en) | 2006-01-25 | 2010-05-05 | Synta Pharmaceuticals Corp | THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY |
| US7951824B2 (en) * | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
| EP2081905B1 (en) | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| MX2009002888A (es) | 2006-09-25 | 2009-03-31 | Boehringer Ingelheim Int | Compuestos que modulan el receptor cb2. |
| US20100029685A1 (en) * | 2006-10-25 | 2010-02-04 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| GB0622202D0 (en) | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| WO2010033350A1 (en) | 2008-09-16 | 2010-03-25 | Merck & Co., Inc. | Sulfonamide derivative metabotropic glutamate r4 ligands |
-
2011
- 2011-05-12 EP EP11781297.4A patent/EP2568809A4/en not_active Withdrawn
- 2011-05-12 MX MX2012013031A patent/MX2012013031A/es not_active Application Discontinuation
- 2011-05-12 SG SG2012081162A patent/SG185414A1/en unknown
- 2011-05-12 WO PCT/US2011/036308 patent/WO2011143466A1/en not_active Ceased
- 2011-05-12 CA CA2798514A patent/CA2798514A1/en not_active Abandoned
- 2011-05-12 CN CN201180029055XA patent/CN102939006A/zh active Pending
- 2011-05-12 RU RU2012154447/04A patent/RU2012154447A/ru not_active Application Discontinuation
- 2011-05-12 BR BR112012028894A patent/BR112012028894A2/pt not_active IP Right Cessation
- 2011-05-12 KR KR1020127032242A patent/KR20130079429A/ko not_active Withdrawn
- 2011-05-12 JP JP2013510307A patent/JP2013526544A/ja not_active Withdrawn
- 2011-05-12 US US13/697,783 patent/US9192603B2/en active Active
- 2011-05-12 AU AU2011252974A patent/AU2011252974A1/en not_active Abandoned
-
2012
- 2012-11-05 IL IL222854A patent/IL222854A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012028894A2 (pt) | 2019-09-24 |
| US9192603B2 (en) | 2015-11-24 |
| CN102939006A (zh) | 2013-02-20 |
| MX2012013031A (es) | 2012-12-17 |
| SG185414A1 (en) | 2012-12-28 |
| EP2568809A4 (en) | 2013-11-06 |
| WO2011143466A1 (en) | 2011-11-17 |
| US20130158078A1 (en) | 2013-06-20 |
| JP2013526544A (ja) | 2013-06-24 |
| EP2568809A1 (en) | 2013-03-20 |
| KR20130079429A (ko) | 2013-07-10 |
| AU2011252974A1 (en) | 2012-12-13 |
| IL222854A0 (en) | 2012-12-31 |
| CA2798514A1 (en) | 2011-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012154447A (ru) | Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций | |
| RU2012121631A (ru) | АРИЛ- И ГЕТЕРОАРИЛСУЛЬФОНЫ КАК АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ | |
| RU2012114770A (ru) | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ | |
| AU2021225157B2 (en) | Combination therapy of tetracyclic quinolone analogs for treating cancer | |
| RU2012139491A (ru) | Бензизоксазолы и азабензизоксазолы как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций | |
| AU2015256075B2 (en) | Combinations of NMDAR modulating compounds | |
| RU2744988C2 (ru) | Соединения и композиции для подавления активности shp2 | |
| EP3340982B1 (en) | Compounds for treatment of immune and inflammatory disorders | |
| RU2012121630A (ru) | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4 КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ | |
| JP2013526544A5 (enExample) | ||
| CN102497862B (zh) | 使用ck2调节剂的组合治疗 | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| RU2011141123A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RAF-КИНАЗ | |
| US20130224151A1 (en) | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | |
| JP2024072291A (ja) | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 | |
| JP2019510039A (ja) | 新規組成物および方法 | |
| US20150080404A1 (en) | Novel compositions and methods | |
| TW201316991A (zh) | Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合 | |
| NZ596739A (en) | Methods of treating proliferative diseases | |
| HRP20191029T1 (hr) | Derivati morfinana radi liječenja predoziranja lijekom | |
| WO2014083327A1 (en) | Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy | |
| JP2023506787A (ja) | Ｐａｒｐ阻害薬と組み合わせたａｔｒ阻害薬の使用 | |
| ES2694352T3 (es) | Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas | |
| JP7737721B2 (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| RU2013130926A (ru) | Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20140513 |